Allergic Rhinitis Treatment Market Estimated to Value at US$ 17,863.6 Million by 2027
Global Allergic Rhinitis Treatment Market
Allergic rhinitis, also known as hay fever, is an IgE-mediated disorder caused by allergens, such as mold or tress, animal, dander, house dust mites, weed pollens, and grass. The disease can occur in two different forms, namely, seasonal and perennial, and can cause mild or moderate-to-severe inflammation inside the nose. Some of the major symptoms of allergic rhinitis include nasal congestion, rhinorrhea, sneezing, nasal itching, and itchy eyes. It is believed that allergic rhinitis and sinusitis are linked to each other, as allergic rhinitis blocks the nose, which in turn, blocks the sinuses. In 2015, according to the World Allergy Organization, over 400 million people suffered from allergic rhinitis worldwide. Moreover, in the U.S., 10% to 30% adults and around 40% children were affected by allergic rhinitis.
Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/1201
Global Allergic Rhinitis Treatment Market Taxonomy
By Drug Class:
- Intranasal Corticosteroids
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://bit.ly/3qPb7vZ
Introduction of new drugs is expected to drive global market growth
Manufacturers have been developing a variety of drugs and nasal sprays for the treatment of allergic rhinitis. This, in turn, is expected to fuel the growth of the global Allergic Rhinitis Treatment market in the near future. For instance, in March 2017, the U.S. Food and Drug Administration (FDA) approved Odactra drug, manufactured by Catalent Pharma Solutions Limited, the first allergen extract to be administered under the tongue (sublingually), to treat house dust mite (HDM)-induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis), for people aged between18 and 65 years.
In 2016, Aralez Pharmaceutical Inc. launched Blexten, for the treatment of symptoms related to seasonal allergic rhinitis (SAR) and chronic spontaneous urticarial (CSU) in Canada. Moreover, in January 2017, Pediapharm Inc. launched an innovative allergy medication – Rupall, in a tablet and oral form, which is a first prescription antihistamine with three indications namely, symptoms associated with seasonal allergic rhinitis (SAR), perennial allergic rhinitis (PAR), and chronic spontaneous urticaria (CSU), for people aged 2 years and above suffering from the allergy. Moreover, growing drug pipeline for the treatment of allergy rhinitis is expected to contribute substantially to the global market growth. For instance, GenMont Biotech is developing eN-Lac for the treatment of allergy rhinitis. The drug is currently in the third phase of development, and will most probably be introduced into the market in the next few years.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/market-insight/allergic-rhinitis-drugs-market-1201
Higher prevalence of allergy rhinitis among the global population is expected to favor market development
Increasing prevalence of allergy rhinitis is a major factor propelling the growth of the Allergic Rhinitis Treatment market in the near future. For instance, in 2012, according to American Academy of Allergy, Asthma, and Immunology, around 17.6 million adults and 6.6 million children were diagnosed with hay fever in the U.S. Moreover, according to International Study on Asthma and Allergies in Childhood (ISAAC), in 2015, prevalence of allergic rhinitis symptoms varied between 0.8 % and 14.9 % in children, aged 6 to 7 years and 1.4 % and 39.7 % in 13 to 14 years old worldwide.
In 2016, the European Academy of Allergy and Clinical Immunology (EAAC) reported that over 150 million of people suffered from chronic allergic diseases in Europe, and it is predicated that around half of the entire population of the region would be severely affected by 2025.
Global Allergic Rhinitis Treatment Market – Key Players
The well-known players in the global Allergic Rhinitis Treatment market include GlaxoSmithKline Plc, Adamis Pharmaceuticals, ALK-Abello, Dr. Reddy’s Laboratories, Allergy Therapeutics, Lupin Pharmaceuticals, Array BioPharma, Hanmi Pharmaceuticals, Mylan NV, and Sun Pharmaceuticals.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/allergic-rhinitis-treatment-market-3349
Table of Content
Global Allergic Rhinitis Treatment Market Research Report
Section 1: Global Allergic Rhinitis Treatment Industry Overview
Section 2: Global Economic Impact on Allergic Rhinitis Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Allergic Rhinitis Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Allergic Rhinitis Treatment Market Forecast
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire